FDA considers 'substantially inferior' heart drug

FDA considers ‘substantially inferior’ heart drug

Image copyright Merck Image caption The first clinical trials of a generic form of the heart attack-preventing drug – known as semagacestat – began in 1997 A panel of the US Food and Drug…